Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cell Carcinoma: early-phase trial registry
50 of 122 indexed Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #100 of 28,707 conditions by registered trial count.
122 US clinical trials · 50 currently recruiting · #100 of 28,707 conditions by registered trial count
Renal Cell Carcinoma: 122 US clinical trials tracked, 50 recruiting.
Renal Cell Carcinoma is the subject of 122 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition renal-cell-carcinoma
OPEN 50 | RECR 41% | LATE 10 | EARLY 90 | RANK #100 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Ovarian Neoplasms (41% recruiting · 39 trials)
Renal Cell Carcinoma lists 50 open slots (41% of 122 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cell Carcinoma is recruiting above its size-band peers.
50 of 122 indexed trials (41%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Renal Cell Carcinoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 7 of 122 trials (5.7%). 87 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Cell Carcinoma enrolment sits around 80 participants.
Median target enrolment is 80 among the 122 trials that report a genuine target (sentinel values excluded). 69 of those (56.6%) plan for fewer than 100 participants.
-
Renal Cell Carcinoma research is mostly interventional.
110 interventional and 12 observational studies make up this index (90.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
122 total, page 2 of 3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Eisai
NCT02811861
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Exelixis
NCT03937219
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb
NCT03141177
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Bristol-Myers Squibb
NCT03873402
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals
NCT04987203
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT03845166
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Merck Sharp & Dohme
NCT06307431
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
NCT05805501
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics
NCT05239143
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo
NCT04707248
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Merck Sharp & Dohme
NCT06099782
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center
NCT01224288
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03634540
Evaluation of a Simple-Prep Controlled Embolic
Fluidx Medical Technology
NCT06453642
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02293980
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
NCT03172754
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen
NCT03294083
Follow-up After Metastasectomy in Patients With Kidney Cancer
M.D. Anderson Cancer Center
NCT00918775
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
NCT02306954
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT04074967
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb
NCT05013099
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Merck Sharp & Dohme
NCT05468697
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Bradley A. McGregor, MD
NCT04413123
ITIL-306 in Advanced Solid Tumors
Instil Bio
NCT05397093
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
M.D. Anderson Cancer Center
NCT05501054
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT00715442
High Dose IL 2 and Entinostat in RCC
Roberto Pili
NCT03501381
PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology
UNC Lineberger Comprehensive Cancer Center
NCT05592665
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT03541902
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
Children's Hospital Medical Center, Cincinnati
NCT03630536
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
NCT04495257
Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
University of Texas Southwestern Medical Center
NCT02473536
177LuPSMA in Renal Cell Carcinoma
Dana-Farber Cancer Institute
NCT06964958
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
NCT04022343
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
National Cancer Institute (NCI)
NCT00340457
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Exelixis
NCT01865747
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
Agenus
NCT00033904
Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
Pfizer
NCT04309617
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Pfizer
NCT00474786
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Novartis Pharmaceuticals
NCT00903175
NANOTECH RCC Biomarkers
Washington University School of Medicine
NCT02923284
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 39 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cell Carcinoma page
122 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cell Carcinoma condition card totals 122 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.